Sharing their personal Lyme stories informs and inspires.
By Dorothy Kupcha Leland
Much-awaited sequel follows old friends and introduces new voices.
By Dorothy Kupcha Leland
Protests and events draw attention to compromised patient care.
By Sandi Bohle
Why the IDSA guideline development process matters to patients.
By Lorraine Johnson, JD, MBA
Patient groups file comments critizing IDSA guideline development process.
By Lorraine Johnson, JD, MBA
LDo’s new patient-powered research tool promises better treatment for Lyme.
By Lorraine Johnson, JD, MBA
LDo surveys provide patients a voice in policy debate.
By Phyllis Mervine. EdM
Johns Hopkins study of huge insurance database exposes high cost of chronic Lyme.
By Phyllis Mervine. EdM
Average annual cost exceeds $10K per patient or $3B nationally based on new CDC figures.
By Lorraine Johnson, JD, MBA
FDA proposed policy changes could stiffle Lyme test innovation.
By Lorraine Johnson, JD, MBA
Synthetic antigen may improve the sensitivity of Lyme Western blots.
By Jyotsna Shah, PhD, CMLD, MBA
Proposed framework favors insurance companies and big pharma at the expense of patients.
By Christine Green, MD
When Lyme steals everything, you will spend every last cent trying to get well.
By Jenny Buttaccio
My most frightening and frustrating symptoms are invisible to everyone else.
By Judy Starling
Subscribe to our mailing list and get Lyme disease news updates to your email inbox.
We respect your privacy and take protecting it seriously.